Janus kinase inhibition and symptom control in myeloproliferative neoplasms

Click to increase image sizeClick to decrease image size

Transparency

Declaration of funding

This work was supported in part by the MD Anderson Cancer Center support grant P30 CA016672 from the National Cancer Institute (National Institutes of Health).

Declaration of financial/other relationships

M.S. has no financial disclosures. P.B. has received research support from Incyte corporation, Celgene corporation, CTI Biopharma, Blueprint Medicines Corporation, Astellas, and Pfizer.

CMRO peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Acknowledgments

None.